Operating
Accrued expenses and other liabilities
Vertex Pharmaceuticals Accrued expenses and other liabilities increased by 110.6% to $70.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 46.6%, from $48.10M to $70.50M.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryLiquidity
SignalContext dependent
VolatilityModerate
First reportedQ1 2013
Last reportedQ1 2026May 5, 2026
How to read this metric
An increase in accrued liabilities provides a source of cash (delaying payment), while a decrease represents a cash outflow as obligations are settled.
Detailed definition
This represents the change in obligations for expenses incurred but not yet paid in cash. It is a key component of worki...
Peer comparison
Standard working capital metric; peers in the tech sector typically show similar trends based on their payment terms with suppliers.
Metric ID:
operating_increase_decrease_in_accrued_liabilities_and_o_c85a76Historical Data
17 periods
| Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $146.70M | $51.20M | $61.60M | $485.50M | $433.20M | $140.70M | $276.70M | $368.70M | $107.35M | $194.10M | $168.30M | $170.60M | $48.10M | $166.60M | $332.90M | -$664.50M | $70.50M |
| QoQ Change | — | -65.1% | +20.3% | +688.1% | -10.8% | -67.5% | +96.7% | +33.2% | -70.9% | +80.8% | -13.3% | +1.4% | -71.8% | +246.4% | +99.8% | -299.6% | +110.6% |
| YoY Change | — | — | — | — | +195.3% | +128.4% | -43.0% | -14.9% | — | +38.0% | -39.2% | -53.7% | -75.2% | -1.0% | +95.1% | — | +46.6% |
Range-$664.50M – $485.50M
CAGR-16.7%
Avg YoY Growth+25.1%
Median YoY Growth-1.0%
Accrued expenses and other liabilities at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's accrued expenses and other liabilities?
- Vertex Pharmaceuticals (VRTX) reported accrued expenses and other liabilities of $70.50M in Q1 2026.
- How has Vertex Pharmaceuticals's accrued expenses and other liabilities changed year-over-year?
- Vertex Pharmaceuticals's accrued expenses and other liabilities increased by 46.6% year-over-year, from $48.10M to $70.50M.
- What does accrued expenses and other liabilities mean?
- The net change in expenses that have been recorded but not yet paid.